Fig. 5: Targeting EPCs metabolic reprogramming. | npj Precision Oncology

Fig. 5: Targeting EPCs metabolic reprogramming.

From: Targeting erythroid progenitor cell metabolism to enhance cancer immunotherapy

Fig. 5: Targeting EPCs metabolic reprogramming.The alternative text for this image may have been generated using AI.

A deeper understanding of the metabolic mechanisms of EPCs and their influence on the metabolism of other cells may enable the development of metabolism-based biomarkers for guiding clinical therapy. Additionally, targeting EPCs metabolism could enhance the efficacy of cancer immunotherapy, ultimately improving patient outcomes. EPC erythroid progenitor cell, EDMC erythroid-derived myeloid cell, ADC antibody-drug conjugate.

Back to article page